At this year’s ACR Convergence Great Debate, Michelle Petri, MD, MPH, and Brad Rovin, MD, discuss their preferred choice of add-on drug – belimumab or voclosporin – to standard lupus nephritis therapy.
Researchers analyzed mortality trends in lupus nephritis in the US from 1999 to 2019 and identified population characteristics associated with mortality.
In a second interim analysis of the AURORA 2 extension study, researchers reported on the effects of voclosporin on lupus nephritis.
Renal response at 6 months strongly predicted belimumab’s durability.
The risk of lupus nephritis flares decreased with belimumab treatment, investigators reported.
Recent approval of new drugs for lupus nephritis and promising therapies on the horizon bode well for the care of patients with the kidney disorder.
The management recommendations for lupus nephritis are poised to change significantly in the coming months, a KDIGO committee revealed.
Improving access to kidney transplantation for patients with lupus nephritis could significantly reduce their cardiovascular morbidity, according to investigators.
Investigators speculate that a novel target of autoimmunity in LN that affects renal tubular potassium transport results in idiopathic hypokalemia in patients with LN.
Among children on dialysis, those with lupus nephritis were more likely to be hospitalized.
